With Huang Medicine: Enroll patients in the SANOVO China Phase III study for combined therapy with Xalkori and Tarceva for first-line treatment of specific lung cancer patients.

On the morning of August 20th, Hutchison China MediTech Limited announced on the Hong Kong Stock Exchange that patient enrollment for the SANOVO China Phase III study for the combination therapy of Vizimpro and Tepmetko in first-line treatment of specific non-small cell lung cancer patients with epidermal growth factor receptor mutations and MET overexpression has been completed. The last patient for this study was enrolled on August 18, 2025. The topline results of the SANOVO study are expected to be announced in the second half of 2026, and will subsequently be submitted for publication at appropriate academic conferences. If the results are positive, Hutchison China MediTech Limited will initiate plans to submit a new indication application to the National Medical Products Administration.